SMMT - Summit Therapeutics plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.5000
+0.0200 (+1.35%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4800
Open1.5000
Bid1.22 x 1000
Ask1.62 x 1000
Day's Range1.4100 - 1.5000
52 Week Range1.1000 - 15.9000
Volume19,973
Avg. Volume32,879
Market Cap51.185M
Beta (3Y Monthly)1.31
PE Ratio (TTM)1.22
EPS (TTM)1.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.60
Trade prices are not sourced from all markets
  • PR Newswire19 hours ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • GlobeNewswire3 days ago

    Holding(s) in Company

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if.

  • GlobeNewswire4 days ago

    Award of Restricted Stock Units

    Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Award of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 14 January 2019 - Summit Therapeutics (AIM:.

  • GlobeNewswire8 days ago

    Holding(s) in Company

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if.

  • GlobeNewswire8 days ago

    Completion of $25 million subscription

    Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics.

  • GlobeNewswire9 days ago

    Holding(s) in Company

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if.

  • GlobeNewswire10 days ago

    Update on Admission

    Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Subscription to Raise $25m Oxford, UK, and Cambridge, MA, US, 8 January 2019 - Summit Therapeutics (AIM:.

  • GlobeNewswire14 days ago

    Result of General Meeting

    Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that at a general meeting of the Company held today in London, in connection with the proposed subscription to raise $25 million announced by the Company on 17 December 2018 (the “Subscription”), all of the resolutions were duly approved by shareholders by way of a poll. Completion of the Subscription is expected to occur on 8 January 2019. Application has been made for the 78,125,000 new ordinary shares, which will be represented by 15,625,000 American Depositary Shares and issued in connection with the Subscription, are expected to be admitted to trading on AIM on 8 January 2019 (“Admission”).

  • Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
    Zacks15 days ago

    Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

    Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

  • GlobeNewswirelast month

    Holding(s) in Company

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if.

  • GlobeNewswirelast month

    Proposed Subscription to Raise $25m and Notice of General Meeting

    THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR AN INVITATION TO ACQUIRE OR DISPOSE OF ANY SECURITIES. YOUR ATTENTION IS ALSO DRAWN TO THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

  • GlobeNewswirelast month

    3rd Quarter Results

    Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and.

  • GlobeNewswirelast month

    Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018

    Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11.

  • GlobeNewswire2 months ago

    Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week

    Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, marks the start of Antibiotics Awareness Week today by highlighting the importance of innovation in the discovery and development of new antibiotics. “As bacteria render existing classes of antibiotics less and less effective, infectious diseases are an ever-increasing threat to human life.

  • GlobeNewswire2 months ago

    Appointment of Joint Broker

    Summit Therapeutics plc  (‘Summit’ or the ’Company’) Appointment of Joint Broker Oxford, UK, and Cambridge, MA, US, 12 November 2018 – Summit Therapeutics plc (NASDAQ:.

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on OUTFRONT Media, Limoneira, Papa John's International, Everi, Premier, and Summit Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Holding(s) in Company

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if.

  • GlobeNewswire3 months ago

    Summit Recognises C. difficile Awareness Month

    Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, recognises C. difficile Awareness Month, which highlights the common, but largely unknown C. difficile infection (CDI) throughout the month of November. C. difficile infects over one million patients in the US and Europe each year, causing inflammation and severe diarrhoea that can be fatal. Summit is developing the Phase 3-ready precision antibiotic ridinilazole to address both the initial infection and importantly the key unmet need of reducing recurrence of CDI.

  • GlobeNewswire3 months ago

    Director/PDMR Shareholding

    Summit Therapeutics plc  (‘Summit’ or the ’Company’) Exercise of Restricted Stock Units, Director Dealings and Total Voting Rights Oxford, UK, and Cambridge, MA, US, 24.

  • GlobeNewswire3 months ago

    Award of Share Options

    Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces the grant of options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) on 19 October 2018 to the Chief Executive Officer, PDMRs and other employees in line with the Company’s Long Term Incentive Plan. The Remuneration Committee of the Board of Directors determined that this award of share options is the optimal way to re-incentivise its employees as the Company seeks to deliver its strategy of creating a successful antibiotics business.